Show simple item record

dc.contributor.authorSewell, GJ
dc.contributor.authorKaestner, S
dc.date.accessioned2015-10-27T16:27:31Z
dc.date.available2015-10-27T16:27:31Z
dc.date.issued2007
dc.identifier.issn1078-1552
dc.identifier.issn1477-092X
dc.identifier.urihttp://hdl.handle.net/10026.1/3716
dc.description.abstract

<jats:p> Background. In dose-banding (DB) prescribed doses of cancer chemotherapy are fitted to doseranges or ‘bands’ and standard doses for each band are provided using a selection of pre-filled infusions or syringes, either singly or in combination. DB is used for several drugs where dose is based on body surface area. No DB-scheme has been reported for carboplatin, which, in clinical practice, is routinely dosed according to renal function. </jats:p><jats:p> Study objective. To assess the rationale for DB of carboplatin with regards to factors that influence dosing accuracy, develop a DB scheme, and discuss its potential use and limitations. </jats:p><jats:p> Methods. Prospective evaluations of carboplatin area under the plasma concentration – time curve (AUC) following application of the Calvert-formula were identified by a literature search. A relevant carboplatin dose range for construction of a DB-scheme with Calvert-formula based doses was obtained from published glomerular filtration rate distributions for patients receiving carboplatin. </jats:p><jats:p> Results. A DB-scheme was developed for individually calculated carboplatin doses of 358–1232 mg, with 35 mg increments between each standard dose and a maximum deviation of 4.7% from prescribed dose. The proposed DB-scheme covers the GFR-ranges 47–221 mL/min and 26–151 mL/min for patients receiving doses based on the target AUCs of 5 and 7 mg/mL/min, respectively. </jats:p><jats:p> Conclusion. There is a strong scientific rationale to support DB of carboplatin. The proposed banding scheme could introduce benefits to patients and healthcare staff but, as with other DB schemes, should be validated with prospective clinical and pharmacokinetic studies to confirm safety and efficacy. </jats:p>

dc.format.extent109-117
dc.format.mediumPrint
dc.languageen
dc.language.isoen
dc.publisherSAGE Publications
dc.subjectAntineoplastic Agents
dc.subjectArea Under Curve
dc.subjectCarboplatin
dc.subjectDose-Response Relationship, Drug
dc.subjectDrug Monitoring
dc.subjectGlomerular Filtration Rate
dc.subjectHumans
dc.subjectNeoplasms
dc.subjectProspective Studies
dc.subjectQuality Control
dc.titleDose-banding of carboplatin: Rationale and proposed banding scheme
dc.typejournal-article
dc.typeArticle
plymouth.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/17873111
plymouth.issue2
plymouth.volume13
plymouth.publisher-urlhttp://dx.doi.org/10.1177/1078155207080801
plymouth.publication-statusPublished
plymouth.journalJournal of Oncology Pharmacy Practice
dc.identifier.doi10.1177/1078155207080801
plymouth.organisational-group/Plymouth
plymouth.organisational-group/Plymouth/Faculty of Health
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA03 Allied Health Professions, Dentistry, Nursing and Pharmacy
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA03 Allied Health Professions, Dentistry, Nursing and Pharmacy/UoA03 Allied Health Professions, Dentistry, Nursing and Pharmacy MANUAL
plymouth.organisational-group/Plymouth/Research Groups
plymouth.organisational-group/Plymouth/Research Groups/Institute of Health and Community
plymouth.organisational-group/Plymouth/Users by role
dc.publisher.placeEngland
dc.identifier.eissn1477-092X
dc.rights.embargoperiodNot known
rioxxterms.versionofrecord10.1177/1078155207080801
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.typeJournal Article/Review


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV